Brief Title
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
Official Title
Maintenance of Remission After Discontinuation of Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
Brief Summary
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control. Discontinuation of treatment is therefore most often decided by the practitioner, on the basis of his experience and knowledge of the patient, the long-term course with somatostatin analogues being very little described. Thus, although hormonal control is achieved in a majority of cases under medical treatment, we do not know if it is possible to stop treatment and in this case how the pathology evolves. It would appear that approximately 40% of patients defined as very good responders to somatostatin analogues may gradually space their injections.
Study Type
Observational
Primary Outcome
Study of the clinical and biological evolution, after discontinuation of treatment with somatostatin analogues, of acromegalic patients with recurrence after surgery.
Condition
Acromegaly
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
100
Start Date
October 1, 2021
Completion Date
March 20, 2023
Primary Completion Date
March 2023
Eligibility Criteria
Inclusion criteria: - Major subject (≥18 years old) - Having been seen at least once in consultation in the Internal Medicine, Endocrinology and Nutrition department of Hautepierre Hospital - Subject operated for a pituitary adenoma at the HUS between 01/01/2000 to 09/01/2021 - In whom biological confirmation of recurrence has been demonstrated - Patient not having expressed his opposition, after information, to the reuse of his data for scientific research purposes. Exclusion criteria: - Subject having expressed opposition to participating in the study - Treatment pre and / or post surgery by radiotherapy - No recurrence - No treatment with a somatostatin analogue for recurrence - Subject under guardianship, curatorship or safeguard of justice
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Philippe BALTZINGER, MD, 33 3 88 12 75 82, [email protected]
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT05149495
Organization ID
8409
Responsible Party
Sponsor
Study Sponsor
University Hospital, Strasbourg, France
Study Sponsor
Philippe BALTZINGER, MD, Principal Investigator, Service Médecine Interne, Endocrinologie et Nutrition - Hôpitaux Universitaires de Strasbourg
Verification Date
November 2021